EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS

INTRODUCTION: The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no longer recommends a long-acting β(2)-agonist (LABA) plus inhaled corticosteroid (ICS) combination for the treatment of chronic obstructive pulmonary disease (COPD). In patients treated with LABA/ICS, who continue...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhl, Roland, Dreher, Michael, Mattiucci-Guehlke, Muriel, Emerson-Stadler, Rachel, Eckhardt, Sebastian, Taube, Christian, Vogelmeier, Claus F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230142/
https://www.ncbi.nlm.nih.gov/pubmed/37256536
http://dx.doi.org/10.1007/s12325-023-02524-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230142/
https://www.ncbi.nlm.nih.gov/pubmed/37256536
http://dx.doi.org/10.1007/s12325-023-02524-y

Ejemplares similares